Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|3|330-342

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.3, 2015-08, pp. : 330-342

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 428-440

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 8, 2015-08 ,pp. : 866-874

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: effectiveness of split‐dose certolizumab pegol for Crohn's disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1412-1412

John Wiley & Sons Inc

Access to resources Recommend Favorite

Certolizumab pegol for the treatment of rheumatoid arthritis

By Modesto I   Spinello M   Nicchi F   Cottone M  

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 391-402

Future Medicine

Access to resources Recommend Favorite

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 2151-464X, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite